Carter Jennifer M. 4
4 · Augmedix, Inc. · Filed Oct 7, 2020
Insider Transaction Report
Form 4
Augmedix, Inc.NONE
Carter Jennifer M.
Director10% Owner
Transactions
- Purchase
Common Stock
2020-10-05$3.00/sh+666,666$1,999,998→ 3,935,106 total(indirect: See footnote) - Award
Common Stock
2020-10-05+3,268,440→ 3,268,440 total(indirect: See footnote) - Award
Warrant (right to buy)
2020-10-05+303,893→ 303,893 total(indirect: See footnote)Exercise: $2.88Exp: 2029-09-02→ Common Stock (303,893 underlying)
Footnotes (3)
- [F1]On October 5, 2020, the Issuer's wholly-owned subsidiary, August Acquisition Corp. ("Acquisition Sub"), merged with and into Augmedix, Inc., a privately held Delaware corporation ("Augmedix"). Pursuant to this transaction (the "Merger"), Augmedix was the surviving corporation and became the Issuer's wholly owned subsidiary. All of the outstanding shares of stock of Augmedix held by accredited investors were converted into shares of the Issuer's common stock. All of the outstanding warrants, options and stock appreciation rights of Augmedix were assumed by the Issuer.
- [F2]These securities are held of record by McKesson Ventures LLC ("McKesson"). The Reporting Person, a member of the Issuer's board of directors, is an executive vice president and chief strategy and business development officer at McKesson. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any.
- [F3]The warrants are fully vested and exerciseable.